Furosemide
- PDF / 150,933 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 44 Downloads / 128 Views
1 S
Bone marrow hypoplasia and pancytopenia: case report A 4-year-old boy developed bone marrow hypoplasia and pancytopenia during treatment with furosemide for severe pulmonary arterial hypertension. The boy, who had recurrent respiratory infections, leucocytopenia and thrombocytopenia, presented with tachypnoea. A detailed evalautaion led to the diagnosis of patent ductus venosus (PDV) complicated by pulmonary arterial hypertension and hypersplenism. Therefore, he started receiving oral furosemide 1 mg/kg twice a day along with tadalafil, spironolactone and bosentan to reduce the pulmonary artery pressure. One month after the treatment initiation, he developed pancytopenia. A bone marrow smear test was performed, which confirmed bone marrow hypoplasia secondary to furosemide. The boy’s furosemide therapy was changed to torsemide. Subsequently, pancytopenia and bone marrow hypoplasia improved. Six month later, his tachypnoea also improved, and an estimated systolic pulmonary artery pressure was found to be 58mm Hg. Further, he underwent PDV banding followed by PDV ligation. After PDV ligation, acute signs of portal hypertension were not observed. His overall condition improved gradually including blood, liver and spleen parameters. Xiao Y, et al. Ligation of patent ductus venosus in a child with pulmonary arterial hypertension and hypersplenism: A case report. Medicine 99: e21849, No. 34, 21 Aug 2020. 803504275 Available from: URL: http://doi.org/10.1097/MD.0000000000021849
0114-9954/20/1824-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 3 Oct 2020 No. 1824
Data Loading...
